Loading...
XNAS
CVRX
Market cap237mUSD
Dec 05, Last price  
9.05USD
1D
-3.21%
1Q
15.73%
IPO
-65.29%
Name

CVRx Inc

Chart & Performance

D1W1MN
XNAS:CVRX chart
P/E
P/S
4.62
EPS
Div Yield, %
Shrs. gr., 5y
3.21%
Rev. gr., 5y
52.31%
Revenues
51m
+30.53%
6,257,0006,053,00013,036,00022,469,00039,295,00051,292,000
Net income
-60m
L+45.55%
-14,633,000-14,109,000-43,078,000-41,428,000-41,199,000-59,965,000
CFO
-39m
L+0.32%
-12,785,000-16,096,000-27,732,000-42,677,000-39,021,000-39,144,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
IPO date
Jun 30, 2021
Employees
160
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT